Preview

Современная ревматология

Расширенный поиск

Дестабилизация артериальной гипертензии как осложнение терапии нестероидными противовоспалительными препаратами: значение проблемы

https://doi.org/10.14412/1996-7012-2018-2-64-72

Полный текст:

Аннотация

Нестероидные противовоспалительные препараты (НПВП) – наиболее востребованный инструмент борьбы с болью. К сожалению, НПВП могут вызывать различные нежелательные реакции, среди которых одной из самых частых является развитие или дестабилизация артериальной гипертензии (АГ). По данным контролируемых и наблюдательных исследований, прием НПВП сопровождается повышением уровня артериального давления (АД) в среднем на 2–3 мм рт. ст., а стойкая АГ отмечается у 2–25% больных. Кроме того, НПВП способны снижать эффективность практически всех классов антигипертензивных средств, за исключением блокаторов кальциевых каналов. Клиническое значение АГ, возникшей на фоне приема НПВП, определяется существенным повышением риска развития кардиоваскулярных катастроф – инфаркта, ишемического инсульта и внезапной смерти от кардиоваскулярных причин. Все НПВП (и неселективные «традиционные» препараты, и коксибы) способны оказывать негативное влияние на АД. Поэтому при назначении любых НПВП следует учитывать наличие исходной АГ, проводить регулярный контроль АД и корригировать по необходимости антигипертензивную терапию.

В настоящем обзоре рассмотрены ключевые аспекты проблемы НПВП-ассоциированной АГ. 

Об авторе

А. Е. Каратеев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А


Литература

1. Каратеев АЕ. Проект национальных клинических рекомендаций (основные положения). Рациональное использование нестероидных противовоспалительных препаратов по результатам совещания группы экспертов, Москва, 01.04.2017. Научно-практическая ревматология. 2017;55(4):452-6. [Karateev AE. Draft national clinical guidelines (general provisions). Rational use of nonsteroidal antiinflammatory drugs. According to the results of the expert group meeting, Moscow, 01.04.2017. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2017;55(4):452-6. (In Russ.)]. doi:10.14412/ 1995-4484-2017-452-456

2. Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015 Mar 19;13:55. doi: 10.1186/s12916-015-0285-8.

3. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 2013; 16(5):821-47.

4. Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):43-50. doi: 10.1002/pds.3463. Epub 2013 May 30.

5. Sarganas G, Buttery AK, Zhuang W, et al. Prevalence, trends, patterns and associations of analgesic use in Germany. BMC Pharmacol Toxicol. 2015 Oct 1;16:28. doi: 10.1186/s40360-015-0028-7.

6. Wang P, Avorn J, Brookhart M, et al. Effects of noncardiovascular comorbidities on anti-hypertensive use in elderly hypertensives. Hypertension. 2005 Aug;46(2):273-9. Epub 2005 Jun 27.

7. Каратеев АЕ, Попкова ТВ, Новикова ДС и др. Оценка риска желудочно-кишечных и сердечно-сосудистых осложнений, ассоциированных с приемом нестероидных противовоспалительных препаратов в популяции СНГ: предварительные данные эпидемиологического исследования КОРОНА-2. Научно-практическая ревматология. 2014;52(6):600–6. [Karateev AE, Popkova TV, Novikova DS, et al. Assessment of risk for gastrointestinal and cardiovascular complications associated with the use of nonsteroidal anti-inflammatory drugs in the cis population: preliminary data of the CORONA-2 epidemiological survey. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(6):600–6. (In Russ.)]. doi: 10.14412/ 1995-4484-2014-600-606

8. Чазова ИЕ, Жернакова ЮВ, Ощепкова ЕВ и др. Распространенность факторов риска развития сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014;(10):4-12. [Chazova IE, Zhernakova YuV, Oshchepkova EV, et al. Prevalence of cardiovascular risk factors in the Russian population of patients with arterial hypertension. Kardiologiya. 2014;(10): 4-12. (In Russ.)].

9. Здравоохранение в России. Статистический сборник. Москва: Росстат; 2017. 170 с. [Zdravookhranenie v Rossii. Statisticheskii sbornik [Healthcare in Russia. Statistical compendium]. Moscow: Rosstat; 2017. 170 p.]

10. Reboussin DM, Allen NB, Griswold ME, et al. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA /ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017 Nov 7. pii: S0735-1097(17) 41517-8. doi: 10.1016/j.jacc.2017.11.004. [Epub ahead of print]

11. Lovell AR, Ernst ME. Drug-Induced Hypertension: Focus on Mechanisms and Management. Curr Hypertens Rep. 2017 May; 19(5):39. doi: 10.1007/s11906-017-0736-z.

12. Salort-Llorca C, Minguez-Serra MP, Silvestre-Donat FJ. Interactions between ibuprofen and antihypertensive drugs: incidence and clinical relevance in dental practice. Med Oral Patol Oral Cir Bucal. 2008 Nov 1;13(11):E717-21.

13. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993 Feb 22;153(4):477-84.

14. Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol. 2018 Feb 21. doi: 10.1111/bph.14167. [Epub ahead of print]

15. Harris C, Breyer M. Update on Cyclooxygenase-2 Inhibitors. Clin J Am Soc Nephrol. 2006 Mar;1(2):236-45. Epub 2006 Feb 1.

16. Cheng HF, Harris RC. Cyclooxygenases, the kidney, and hypertension. Hypertension. 2004 Mar;43(3):525-30. Epub 2004 Jan 19.

17. Singh G, Miller JD, Lee FH, et al. Pevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination survey. Am J Manag Care. 2002 Oct;8(15 Suppl):S383-91.

18. Harley C, Wagner S. The prevalence of cardiovascular risk factors in parients prescribing anti-inflammatory drugs; data from managed care. Clin Ther. 2003 Jan;25(1):139-49.

19. Curhan G, Willet W, Rosner B, Stampfer M. Frequency оf analgestic use and risk of hypertension in younger woman. Arch Intern Med. 2002 Oct 28;162(19):2204-8.

20. Formam J, Stampfer M, Curhan G. Nonnarcotic analgetic dose and risk of incident hypertension in US women. Hypertension. 2005 Sep;46(3):500-7. Epub 2005 Aug 15.

21. Solomon D, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004 Aug;44(2):140-5. Epub 2004 Jun 28.

22. Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006 Sep 5;114(10):1028-35.

23. Silverstein F, Faich G, Goldstein J, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxid long-term arthritis safety study. JAMA. 2000 Sep 13;284(10):1247-55.

24. Singh G, Fort J, Goldstein J, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med. 2006 Mar;119(3):255-66.

25. Cannon C, Curtis S, FitzGerald G, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Longterm (MEDAL) programme: a randomised comparison. Lancet. 2006 Nov 18;368(9549): 1771-81.

26. Sowers J, White W, Pitt B, et al. The effects of cycloxygenase -2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-houar blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005 Jan 24;165(2):161-8.

27. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375(26):2519-29. doi: 10.1056/NEJMoa1611593. Epub 2016 Nov 13.

28. Ruschitzka F, Borer JS, Krum H, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J. 2017 Nov 21; 38(44):3282-3292. doi:10.1093/eurheartj/ehx508.

29. White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007 Jan 1; 99(1):91-8. Epub 2006 Nov 10.

30. Elliott WJ. Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality? Curr Hypertens Rep. 2010 Aug;12(4):258-66. doi: 10.1007/s11906-010-0120-8.

31. Krum H, Swergold G, Curtis SP, et al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009 Apr;27(4):886-93. doi: 10.1097/HJH.0b013e328325d831.

32. Aw T, Haas S, Liew D, Krum H. Metaanalysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005 Mar 14;165(5):490-6. Epub 2005 Feb 14.

33. Chan C, Reid C, Aw T, et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens. 2009 Dec;27(12):2332-41. doi: 10.1097/HJH. 0b013e3283310dc9.

34. Curtis SP, Ng J, Yu Q, et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther. 2004 Jan;26(1):70-83.

35. Bingham CO, Sebba AI, Rubin BR, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford). 2007 Mar;46(3):496-507. Epub 2006 Aug 27.

36. Leung AT, Malmstrom K, Gallacher AE, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and activecomparator controlled 12-week efficacy trial. Curr Med Res Opin. 2002;18(2):49-58.

37. Matsumoto AK, Melian A, Mandel DR, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 2002 Aug;29(8):1623-30.

38. Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. 2004 Feb;50(2):598-606.

39. Dong YH, Chang CH, Wu LC, et al. Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study. Br J Clin Pharmacol. 2018 Feb 22. doi: 10.1111/bcp.13537. [Epub ahead of print]

40. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.

41. Gunter BR, Butler KA, Wallace R, et al. Non-steroidal anti-inflammatory druginduced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther. 2017 Feb;42(1):27-38. doi: 10.1111/jcpt.12484. Epub 2016 Dec 26.

42. Bally M, Dendukuri, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017 May 9;357: j1909. doi: 10.1136/bmj.j1909.

43. Brown J, Dollery C, Valdes G. Interaction of nonsteroidal antiinflammatory drugs with antihypertensove and diuretic agents. Am J Med. 1986 Aug 25;81(2B):43-57.

44. Durao V, Martins Prata M, Pires-Goncalves LM. Modification of antihypertensive effect of beta-adrenoreceptorblocking agents by inhibition of endogenous prostaglandin synthesis. Lancet 1977;12: 1005-1007.

45. Oates JA. Antagonism of antihypertensive drug therapy by non-steroidal anti-inflammatory drugs. Hypertension. 1988 Mar;11(3 Pt 2): II4-6.

46. Quilley J, Duchin K, Hudes E, McGiff J. The antihypertensive effect of captopril in essential hypertension. Relationship to prostaglandins and kallikrein-kinin system. J Hypertens. 1987 Feb;5(1):121-8.

47. Salvetti A, Pedrinalli R, Magagna A, Ugenti P. Differential effects of selective and non-selective prostaglandin-synthesis inhibition on pharmacological response to captopril in patients with essential hypertension. Clin. Sci. 1982;63:261-3.

48. Watkins J, Abbott E, Hensby C, et al. Attenuation of hypotensive effect of propranalol and thiaside diuretics by indomethacin. Br Med J. 1980 Sep 13;281(6242): 702-5.

49. Polonia J, Boaventure J, Gama G, et al. Influence of nonsteroidal antiinflammatory drugs on renal function and 24-hour blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens. 1995 Aug;13(8):925-31.

50. Wong D, Spence J, Lamki L, et al. Effect of nonsteroidal antiinflammatory drugs on control of hypertension of beta-blockers and diuretics. Lancet. 1986 May 3;1(8488): 997-1001.

51. Baez M, Alvarez C, Weilder D. Effects of the non-steroidal anti-inflammatory drugs, piroxicam or sulindac, on the antihypertensive action of propranolol and verapamil. J Hypertens Suppl. 1987 Dec;5(5):S563-6.

52. Cinquegrani M, Liang C. Antihypertensive effects of pinacidil in patients with and without indomethacin pretreatment. Clin Exp Hypertens A. 1988;10(3): 411-31.

53. Hardy B, Bartle W, Myers M, et al. Effects of indomethacin on the pharmaсokinetics of felodipine. Br J Clin Pharmacol. 1988 Nov;26(5):557-62.

54. Houston M, Weir M, Gray J, et al. The effects of non-steroidal antiinflammatory drugs on blood pressure of patients with hypertension controlled by verapamil. Arch Intern Med. 1995 May 22;155(10):1049-54.

55. Klassen D, Goadfriend T, Schuma A, et al. Assesment of Blood pressure during treatment with naproxen of ibuprofen in hypertensive patients treated with hydrochlorthiazide. J Clin Pharmacol. 1993 Oct;33(10):971-8.

56. Johnson D, Hisel T, Phillips B. Effect of cyclooxygenase-2 inhibitors on blood pressure. Ann Pharmacother. 2003 Mar;37(3):442-6.

57. Whelton A, Fort J, Puma J, et al. SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001 Mar-Apr;8(2):85-95.

58. Whelton A, White W, Bello A, et al. SUCCESS VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥ 65 years of age with systolic hypertension and osteoarthritis. Am J Cardiol. 2002 Nov 1;90(9):959-63.

59. Dilger K, Herrlinger C, Peters J, et al. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J Clin Pharmacol. 2002 Sep;42(9):985-94.

60. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994 Aug 15;121(4):289-300.

61. Pavlicevic I, Kuzmanic M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol. 2008 Fall;15(3):e372-82. Epub 2008 Oct 24.

62. Aljadhey H, Tu W, Hansen RA, Blalock SJ, et al. Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC Cardiovasc Disord. 2012 Oct 24;12:93. doi: 10.1186/1471-2261-12-93.

63. Villa J, Cano A, Franco D3, et al. Clinical relevance of drug interactions between nonsteroidal antiinflammatory drugs (NSAIDs) and antihypertensives. [Article in Spanish]. Aten Primaria. 2014 Nov;46(9): 464-74. doi: 10.1016/j.aprim.2013.11.010. Epub 2014 Mar 22.

64. Ljungman C, Kahan T, Schiö ler L, et al. Non-steroidal anti-inflammatory drugs and blood pressure control in patients treated for hypertension: results from the Swedish primary care cardiovascular database. Blood Press. 2017 Aug;26(4):220-228. doi: 10.1080/ 08037051.2017.1290503. Epub 2017 Feb 13.

65. Ruff CT, Morrow DA, Jarolim P, et al. Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. J Rheumatol. 2011 Jun;38(6):1071-8. doi: 10.3899/jrheum.100880. Epub 2011 Apr 1.


Для цитирования:


Каратеев А.Е. Дестабилизация артериальной гипертензии как осложнение терапии нестероидными противовоспалительными препаратами: значение проблемы. Современная ревматология. 2018;12(2):64-72. https://doi.org/10.14412/1996-7012-2018-2-64-72

For citation:


Karateev A.E. Destabilized hypertension as a complication of therapy with nonsteroidal anti-inflammatory drugs: the importance of the problem. Modern Rheumatology Journal. 2018;12(2):64-72. (In Russ.) https://doi.org/10.14412/1996-7012-2018-2-64-72

Просмотров: 141


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)